Risperdal, Risperidone News

Medical research out of the University of British Columbia suggests the number of children taking medications known as atypical antipsychotics has increased tenfold over the past decade, CBC News has learned.

Here's a quick look at some atypical antipsychotics prescribed for young people: Risperidone Risperidone, sold under the trade name Risperdal in the United States and Canada, changes the effects of chemicals in the brain, and is used to treat schizophrenia as well as symptoms of bipolar disorder.

From the American Journal of Psychiatry letters to the editor: To The Editor: Salvia divinorum is a sage plant that is easily obtained in the United States.

Although Risperidone Is Now Available In Generics, There Is No Clear Evidence of Expanded Uptake in Early Lines of Therapy, According to a New Report from Decision Resources Patient-Flow Forecasts Need to Take Into Account Shifts in Seroquel XR's Use by Line of Therapy Over the Next Two Years WALTHAM, Mass.

The Food and Drug Administration is in a quandary about whether to give approval for child use of three antipsychotics.

WOODCLIFF LAKE,A N.J. Par Pharmaceutical Cos. has begun shipping its generic version of a drug used to treat schizophrenia and bipolar disorder.

A new instrument for improving patient understanding and acceptance of long-acting injectable antipsychotic therapy has been published in the April edition of Psychiatry 2009.1 This novel, psychosocial approach encompasses Goal setting, Action planning, Initiating treatment, and Nurturing motivation through the use of a clinical discussion tool.

Public release date: 26-May-2009 [ Share ] Contact: Sri Ramaswami Sramaswa@its.jnj.com 908-927-7978 Golin/Harris International New tool to improve patient understanding of long-acting injectable antipsychotic therapies unveiled in April issue of Psychiatry 2009 'GAIN' offers structured approach for physicians to discuss potential reasons for use of ...

Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms.

Schizophrenia is one of the most disabling diseases, and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society.

RISPERDAL CONSTA Long-Acting Treatment Delayed The Time To Relapse In Patients With Bipolar I Disorder New data demonstrate that maintenance therapy with RISPERDAL CONSTA Long-Acting Treatment significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder.

TITUSVILLE,A N.J. The Food and Drug Administration has given approval to a formulation of a Johnson & Johnson drug as a stand-alone and adjunctive treatment for bipolar disorder.

JanssenA , Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has approved the Supplemental New Drug Applications for the use of RISPERDALA CONSTAA Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder.

Vanda Pharmaceuticals Inc. announced today that it will present posters on its newly approved atypical antipsychotic, Fanapt , at the 162nd American Psychiatric Association annual meeting in San Francisco, California.

Shares in Vanda Pharmaceuticals Inc. rocketed into the stratosphere Thursday on news of the FDA's surprising approval of the company's antipsychotic Fanapt.

Shares of Vanda Pharmaceuticals Inc. skyrocketed today after the company said the FDA approved its schizophrenia drug Fanapt.

Correspondence: Dr Manuel J. Cuesta, Psychiatric Unit, Virgen del Camino Hospital c/Irunlarrea 4, E-31008 Pamplona, Spain.

A new Cochrane review finds no evidence to support the use of risperidone to treat attention- deficit/hyperactivity disorder in people with intellectual disabilities, even though the review authors say this is a common prescribing pattern.

Apr 27, 2009 - Alkermes, Inc. today announced that Janssen Pharmaceutica K.K. received approval from the Pharmaceuticals and Medical Devices Agency in Japan to market RISPERDAL CONSTA [ long-acting injection] for the treatment of schizophrenia.

Atypical antipsychotic medications are associated with weight gain and other metabolic changes among patients with Alzheimer's disease, according to a recent analysis of data from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectivenessa 'Alzheimer's Disease study.